|
|
      |
Urine Bone Marker - Dpd (deoxypyridinoline crosslink) Dpd allows physicians to .... Identify patients with increased bone resorption Monitor patients on anti-resorptive trestments Aeron's Dpd assay measures Deoxypyridinoline, a crosslink of Type 1 Collagen found almost exclusively in bone. Elevated values signify increased bone resorption and patients may be at risk of increasing bone fracture. Dpd is released into the circulation during the bone remodeling process, when osteoclasts degrade bone. Dpd is a sensitive and specific marker of bone resorption. The Center for Medicare and Medicaid Services (CMS) mandates coverage and reimbursement for the Dpd assay by all Medicare carriers for testing requested by a licensed medical provider. Aeron is a Medicare contract laboratory provider as well as for Blue Cross, Blue Shield and United Healthcare. Aeron has developed a unique laboratory report format for Dpd. Test results are graphically reported Example Test Report for up to five sequential determinations. Values are plotted and the percent change is calculated between the current and previous assay value. Dpd is excreted unmetabolized in urine and is unaffected by diet, making it suitable for assessing resorption. The Dpd assay should be performed using preservative free first or second morning voided urine collections. Dpd is stable in urine at room temperature for at least two weeks. Like living coral, bone is constantly going through simultaneous degradation and rebuilding; a metabolic process called remodeling. Remodeling is required for the maintenance and overall health of bones and resorption, therefore formation should be maintained in balance. In the process of aging and in certain unregulated metabolic conditions bone resorption begins to exceed formation resulting in a net loss of bone that can lead to osteoporosis and fracture. Reducing elevated bone resorption through supplementation and exercise has been shown to reduce the number of fractures and associated adverse health affects especially in aging populations. Recent in-laboratory studies have identified a combination of supplements that effectively reduce the rated of bone loss in 30 to 90 days of continuous usage. For additional information call Aeron or e-mail Aeron Customer Service. Please put 'Supplements for Bone Loss' in the subject line. Approximately 90% of the organic matrix of bone is type I collagen. Type I collagen is crosslinked by specific molecules such as deoxypyridinoline (DPD), which provides rigidity and strength to bone. Unaffected by diet, DPD is released into the circulation during the bone remodeling process, and excreted unmetabolized in urine. Elevated levels of DPD exceeding the established normal range should be considered potentially harmful and intervention is recommended. Intervention should be monitored at 45 to 90 days and no less than every six months. Bone mineral density testing performed by dual-energy x-ray absorptiometry (DEXA) or urtrasonographic bone densitometry provide a measure of bone mass. It is like a photograph of the bone at a moment in time. It is very possible to have a normal DEXA scan while loosing bone at a rapid rate. Bone density assessment when combined with urine DPD testing results provides the most complete picture of bone health available. DPD is measured using a competitive enzyme immunoassay, utilizing a highly specific monoclonal antibody. Units of measure are stated as NM/mM Cr=nanoMolar deoxypyridinoline (DPD) per milliMolar creatine. The American Association of Clinical Endocrinology Guidelines for Postmenopausal Osteoporosis state:
"Biochemical markers of bone turnover may be useful for the following situations:
The American Medical Association, American College of Clinical Endocrinology, American Society for Bone and Mineral Research and the International Society for Clinical Densitometry has endorsed Dpd testing. Copyright © Aeron Biotechnology Inc., all rights reserved |
